229 related articles for article (PubMed ID: 10698671)
21. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
22. The role of taxanes in the treatment of breast cancer.
Capri G; Tarenzi E; Fulfaro F; Gianni L
Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
24. Drug interactions with the taxanes: clinical implications.
Baker AF; Dorr RT
Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
[TBL] [Abstract][Full Text] [Related]
25. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Valero V; Perez E; Dieras V
Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
Danesi R; Conte PF; Del Tacca M
Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Swift L; McHowat J; Sarvazyan N
Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
[TBL] [Abstract][Full Text] [Related]
29. A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat.
Yeung TK; Simmonds RH; Hopewell JW
Radiother Oncol; 1989 Jul; 15(3):275-84. PubMed ID: 2772255
[TBL] [Abstract][Full Text] [Related]
30. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel.
Pieniążek A; Czepas J; Piasecka-Zelga J; Gwoździński K; Koceva-Chyła A
Adv Med Sci; 2013; 58(1):104-11. PubMed ID: 23612702
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
[TBL] [Abstract][Full Text] [Related]
33. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Colombo T; Parisi I; Zucchetti M; Sessa C; Goldhirsch A; D'Incalci M
Ann Oncol; 1999 Apr; 10(4):391-5. PubMed ID: 10370780
[TBL] [Abstract][Full Text] [Related]
35. Taxane/anthracycline combinations: setting a new standard in breast cancer?
Nabholtz JM; Riva A
Oncologist; 2001; 6 Suppl 3():5-12. PubMed ID: 11346678
[TBL] [Abstract][Full Text] [Related]
36. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
37. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
[TBL] [Abstract][Full Text] [Related]
39. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Pagani O
Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
[TBL] [Abstract][Full Text] [Related]
40. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
